Semaglutide vs Tirzepatide: Key Differences Explained

Side-by-Side Comparison

Clinical trial data from STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) are averages from separate studies with different populations — not a direct head-to-head comparison. Individual results vary. Prices are approximate list prices, subject to change. Always verify with the manufacturer or pharmacy.

Mechanism: What Makes Them Different

The core pharmacological difference between semaglutide and tirzepatide is their receptor targets:

Semaglutide is a GLP-1 receptor agonist. It selectively activates GLP-1 receptors, producing effects on insulin secretion, glucagon suppression, gastric emptying, and appetite. This mechanism is well-established and is the basis for all GLP-1 medications including liraglutide, exenatide, and dulaglutide.

Tirzepatide activates both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone and has receptors in the pancreas, adipose tissue, and brain. The dual activation is believed to produce more robust metabolic and weight effects, though the exact contribution of GIP agonism relative to GLP-1 agonism is still being studied.

Clinical Efficacy: STEP vs. SURMOUNT

Both compounds have been studied in large, well-designed clinical trials for weight management:

Semaglutide — STEP Trials (Wegovy)

• STEP 1: ~14.9% average body weight reduction at 2.4 mg/week over 68 weeks
• STEP 2 (T2D population): ~9.6% average weight reduction
• STEP 3 (with intensive behavioral intervention): ~16% average weight reduction

Tirzepatide — SURMOUNT Trials (Zepbound)

• SURMOUNT-1: ~20.9% average body weight reduction at 15 mg/week over 72 weeks
• SURMOUNT-1 at 10 mg: ~19.5% average weight reduction
• SURMOUNT-2 (T2D population): ~15.7% average weight reduction

Important caveat: STEP and SURMOUNT were separate clinical trials with different patient populations, trial durations, and design elements. They are not direct head-to-head comparisons. The higher average weight loss seen with tirzepatide does not mean every patient will lose more weight with tirzepatide than semaglutide — individual responses vary significantly. Choosing between these compounds is a clinical decision that your prescriber should make with you based on your full medical picture.

Cost Comparison

For weight management (Wegovy vs. Zepbound), approximate list prices as of this writing:

• Wegovy (semaglutide 2.4 mg): ~$1,300–$1,450/month list price
• Zepbound (tirzepatide 10–15 mg): ~$1,000–$1,100/month list price

Actual out-of-pocket cost depends heavily on insurance coverage and savings program eligibility. Eli Lilly has offered self-pay vial options for Zepbound at different price points — verify availability directly with Lilly. For a full cost breakdown, see our GLP-1 cost guide.

Choosing Between Them: A Clinical Decision

The decision between semaglutide and tirzepatide products is not one this site can make for you. It depends on:

• Your medical history, diagnoses, and contraindications
• Your insurance coverage and formulary placement
• Your clinician's assessment of which is most appropriate
• Your tolerance for the escalation schedule and potential side effects
• Availability — shortage situations can affect which products are accessible

A licensed clinician can help you weigh the clinical evidence against your individual situation. This page is intended to help you have a better-informed conversation with your provider — not to replace that conversation.